A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma

Trial Profile

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Nivolumab (Primary) ; Urelumab (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 12 Nov 2016 According to a Bristol-Myers Squibb media release, data were presented at the Society for Immunotherapy of Cancer (SITC) 31 Annual Meeting
    • 12 Nov 2016 Safety and efficacy results including biomarker analyses published in the Bristol-Myers Squibb Media Release
    • 02 Nov 2016 According to a Bristol-Myers Squibb media release, data from this study will be presented at the 2016 Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top